REFERENCES

1. Liu YH, Chen Y, Wang QH, et al. One-year trajectory of cognitive changes in older survivors of COVID-19 in Wuhan, China: a longitudinal cohort study. JAMA Neurol 2022;79:509-17.

2. Mao L, Jin H, Wang M, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol 2020;77:683-90.

3. Huang L, Yao Q, Gu X, et al. 1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study. The Lancet 2021;398:747-58.

4. Heesakkers H, van der Hoeven JG, Corsten S, et al. Clinical outcomes among patients with 1-year survival following intensive care unit treatment for COVID-19. JAMA 2022;327:559-65.

5. Liu YH, Wang YR, Wang QH, et al. Post-infection cognitive impairments in a cohort of elderly patients with COVID-19. Mol Neurodegener 2021;16:48.

6. WHO. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected; 2020. Available from: https://www.scirp.org/reference/referencespapers.aspx?referenceid=2720149 [Last accessed on 30 Jun 2022].

7. Guan WJ, Ni ZY, Hu Y, et al. China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382:1708-20.

8. Odozor CU, Kannampallil T, Ben Abdallah A, et al. Post-acute sensory neurological sequelae in patients with severe acute respiratory syndrome coronavirus 2 infection: the COVID-PN observational cohort study. Pain 2022; doi: 10.1097/j.pain.0000000000002639.

9. Fernández-de-Las-Peñas C, Navarro-Santana M, Gómez-Mayordomo V, et al. Headache as an acute and post-COVID-19 symptom in COVID-19 survivors: A meta-analysis of the current literature. Eur J Neurol 2021;28:3820-5.

10. Silva Andrade B, Siqueira S, de Assis Soares WR, et al. Long-COVID and post-COVID health complications: an up-to-date review on clinical conditions and their possible molecular mechanisms. Viruses 2021;13:700.

11. Merkler AE, Parikh NS, Mir S, et al. Risk of ischemic stroke in patients with coronavirus disease 2019 (COVID-19) vs. patients with influenza. JAMA Neurol 2020; doi: 10.1001/jamaneurol.2020.2730.

12. Luijten LWG, Leonhard SE, van der Eijk AA, et al. IGOS Consortium. Guillain-Barré syndrome after SARS-CoV-2 infection in an international prospective cohort study. Brain 2021;144:3392-404.

13. Lopez-Leon S, Wegman-Ostrosky T, Perelman C, et al. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Sci Rep 2021;11:16144.

14. Eroğlu İ, Eroğlu BÇ, Güven GS. Altered tryptophan absorption and metabolism could underlie long-term symptoms in survivors of coronavirus disease 2019 (COVID-19). Nutrition 2021;90:111308.

15. Marshall M. The lasting misery of coronavirus long-haulers. Nature 2020;585:339-41.

16. Carfì A, Bernabei R, Landi F. for the Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent symptoms in patients after acute COVID-19. JAMA 2020;324:603-5.

17. Xiong Q, Xu M, Li J, et al. Clinical sequelae of COVID-19 survivors in Wuhan, China: a single-centre longitudinal study. Clin Microbiol Infect 2021;27:89-95.

18. Franke C, Ferse C, Kreye J, et al. High frequency of cerebrospinal fluid autoantibodies in COVID-19 patients with neurological symptoms. Brain Behav Immun 2021;93:415-9.

19. Virhammar J, Nääs A, Fällmar D, et al. Biomarkers for central nervous system injury in cerebrospinal fluid are elevated in COVID-19 and associated with neurological symptoms and disease severity. Eur J Neurol 2021;28:3324-31.

20. Tard C, Maurage CA, de Paula AM, et al. Intensive Care Unit Medical Group. Anti-pan-neurofascin IgM in COVID-19-related Guillain-Barré syndrome: evidence for a nodo-paranodopathy. Neurophysiol Clin 2020;50:397-9.

21. Finsterer J. SARS-CoV-2 triggered relapse of multiple sclerosis. Clin Neurol Neurosurg 2022;215:107210.

22. Guedj E, Million M, Dudouet P, et al. ¹⁸F-FDG brain PET hypometabolism in post-SARS-CoV-2 infection: substrate for persistent/delayed disorders? Eur J Nucl Med Mol Imaging 2021;48:592-5.

23. Reiken S, Sittenfeld L, Dridi H, Liu Y, Liu X, Marks AR. Alzheimer’s-like signaling in brains of COVID-19 patients. Alzheimers Dement 2022;18:955-65.

24. Frontera JA, Boutajangout A, Masurkar AV, et al. Comparison of serum neurodegenerative biomarkers among hospitalized COVID-19 patients versus non-COVID subjects with normal cognition, mild cognitive impairment, or Alzheimer's dementia. Alzheimers Dement 2022;18:899-910.

25. Kola L, Kohrt BA, Hanlon C, et al. COVID-19 mental health impact and responses in low-income and middle-income countries: reimagining global mental health. The Lancet Psychiatry 2021;8:535-50.

26. Troitskaya LA, Plotnikova IA, Avakyan GG, et al. Neuropsychological evaluation of cognitive disorders in children after COVID-19. Eur J Transl Myol 2022;32:10685.